From detection to early intervention: A provider’s guide to the identification of drug-induced movement disorders


This webinar is on-demand and can be viewed at your convenience.

The American Psychological Association (APA) recommends that all patients taking antipsychotic medication should be regularly screened for drug-induced movement disorders (DIMDs), including tardive dyskinesia (TD). Yet, despite known risks and significant impacts to patient quality of life, movement disorders may go unmonitored. Studies suggest that 70% of individuals with TD are undiagnosed. However, early screening and recognition of DIMDs can lead to better patient outcomes.

Watch to learn:

  • Best practices for integrating the AIMS assessment into clinical practice in both behavioral health and primary care
  • Strategies for behavioral health leaders and psychiatric clinicians to advocate for movement disorder monitoring within their medical groups or health systems
  • The important role of primary care providers in detecting movement disorders
  • How to leverage the electronic health record (EHR) to assist providers in identifying abnormal involuntary moments at the point of care
 

Presenters:

Jordan Howard Professional Picture (1)

Jordan Howard, MD

CNSL, Privia Health | Adjunct Faculty, Morehouse School of Medicine

suzanneclough-106rtsmall head only

Suzanne Clough, MD

Chief Medical Officer, AmalgamRx

John Poikonen Headshot

John Poikonen, PharmD

Director of Clinical Informatics, AmalgamRx

By registering, you agree to Becker's Healthcare terms of service and privacy policy.